Recombinant Interferon Alpha
Phase 2Small molecule
Recombinant Interferon Alpha is one of 67 small molecule programs targeting Acute Leukemia. It is currently in Phase 2.
2
Indications
4
Total Trials
3
Active Trials
66
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
173 competitors in Acute Leukemia
#DrugCompanyPhaseTrials
1Cytosar
TevaPhase 3
Trexall
Alnylam PharmaceuticalsPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Oncaspar
SServier
Phase 3
Tabloid
Akero TherapeuticsPhase 3
Cerubidine
EEastern Cooperative Oncology Group
Phase 3
Purinethol
SStason
Phase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Essential Thrombocythemia2 trials
Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT04226950·40 enrolled
Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia
Unknown status·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05395507·194 enrolled
Acute Leukemia1 trial
Clinical Study of rhTPO in Hematopoietic Stem Cell Mobilization for Autologous Transplantation in Acute Leukemia
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·N/A·NCT06955858·60 enrolled
Primary Immune Thrombocytopenia (ITP)1 trial
Drug Switching Strategy Study After rhTPO Second-Line Treatment Failure in ITP: A Randomized Controlled Trial Comparing High-Dose rhTPO Versus Eltrombopag
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Preclinical·NCT07476846·112 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details